CRISPR Therapeutics AG

For the period ended Dec 31, 2024. Filed Feb 11, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 11, 2025

CRSP$45.15-9.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

	Years Ended December 31,
	2024	2023	2022
Revenue:
Collaboration revenue	$35,000	$370,000	$436
Grant revenue	2,314	1,206	762
Total revenue	37,314	371,206	1,198
Operating expenses:
Research and development	320,653	387,332	461,645
General and administrative	72,977	76,162	102,464
Collaboration expense, net	110,250	130,250	110,250
Total operating expenses	503,880	593,744	674,359
Loss from operations	(466,566)	(222,538)	(673,161)
Other income:
Other income, net	103,901	71,816	22,661
Total other income, net	103,901	71,816	22,661
Net loss before income taxes	(362,665)	(150,722)	(650,500)
(Provision) benefit for income taxes	(3,587)	(2,888)	325
Net loss	(366,252)	(153,610)	(650,175)
Foreign currency translation adjustment	(21)	73	(80)
Unrealized (loss) gain on marketable securities	(52)	17,487	(10,500)
Comprehensive loss	$(366,325)	$(136,050)	$(660,755)
Net loss per common share — basic	$(4.34)	$(1.94)	$(8.36)
Basic weighted-average common shares outstanding	84,359,126	79,220,930	77,746,575
Net loss per common share — diluted	$(4.34)	$(1.94)	$(8.36)
Diluted weighted-average common shares outstanding	84,359,126	79,220,930	77,746,575

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.